Gollomp SM - Search Results

1

GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding.

Schneider JS, Cambi F, Gollomp SM, Kuwabara H, Brašić JR, Leiby B, Sendek S, Wong DF. Schneider JS, et al. Among authors: gollomp sm. J Neurol Sci. 2015 Sep 15;356(1-2):118-23. doi: 10.1016/j.jns.2015.06.028. Epub 2015 Jun 16. J Neurol Sci. 2015. PMID: 26099170 Free PMC article. Clinical Trial.

2

A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients.

Schneider JS, Gollomp SM, Sendek S, Colcher A, Cambi F, Du W. Schneider JS, et al. Among authors: gollomp sm. J Neurol Sci. 2013 Jan 15;324(1-2):140-8. doi: 10.1016/j.jns.2012.10.024. Epub 2012 Nov 28. J Neurol Sci. 2013. PMID: 23199590 Free PMC article. Clinical Trial.

3

Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.

Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators. Parashos SA, et al. JAMA Neurol. 2014 Jun;71(6):710-6. doi: 10.1001/jamaneurol.2014.391. JAMA Neurol. 2014. PMID: 24711047 Free PMC article. Clinical Trial.

4

Repeatable battery for assessment of neuropsychological status in early Parkinson's disease.

Yang C, Garrett-Mayer E, Schneider JS, Gollomp SM, Tilley BC. Yang C, et al. Among authors: gollomp sm. Mov Disord. 2009 Jul 30;24(10):1453-60. doi: 10.1002/mds.22552. Mov Disord. 2009. PMID: 19452561 Free PMC article.

5

Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.

Truong DD, Gollomp SM, Jankovic J, LeWitt PA, Marx M, Hanschmann A, Fernandez HH; Xeomin US Blepharospasm Study Group. Truong DD, et al. Among authors: gollomp sm. J Neural Transm (Vienna). 2013 Sep;120(9):1345-53. doi: 10.1007/s00702-013-0998-9. Epub 2013 Feb 23. J Neural Transm (Vienna). 2013. PMID: 23435927 Free PMC article. Clinical Trial.

6

A pilot study of botulinum toxin A for headache in cervical dystonia.

Ondo WG, Gollomp S, Galvez-Jimenez N. Ondo WG, et al. Headache. 2005 Sep;45(8):1073-7. doi: 10.1111/j.1526-4610.2005.05190.x. Headache. 2005. PMID: 16109123 Clinical Trial.

7

Alerting psychiatrists to dystonia.

Sadoff RL, Gollomp SM. Sadoff RL, et al. Among authors: gollomp sm. Am J Psychiatry. 1983 Sep;140(9):1258-9. doi: 10.1176/ajp.140.9.1258b. Am J Psychiatry. 1983. PMID: 6614247 No abstract available.

8

Mitigating Immunogenicity by Coordinating Botulinum Toxin Treatments Between Aesthetics and Therapeutics.

Gollomp SM, Khalifian S, Gokhale S. Gollomp SM, et al. Dermatol Surg. 2024 Sep 1;50(9S):S35-S37. doi: 10.1097/DSS.0000000000004295. Dermatol Surg. 2024. PMID: 39196831

9

Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies.

Duda JE, Giasson BI, Chen Q, Gur TL, Hurtig HI, Stern MB, Gollomp SM, Ischiropoulos H, Lee VM, Trojanowski JQ. Duda JE, et al. Among authors: gollomp sm. Am J Pathol. 2000 Nov;157(5):1439-45. doi: 10.1016/S0002-9440(10)64781-5. Am J Pathol. 2000. PMID: 11073803 Free PMC article.

10

Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy.

Duda JE, Giasson BI, Gur TL, Montine TJ, Robertson D, Biaggioni I, Hurtig HI, Stern MB, Gollomp SM, Grossman M, Lee VM, Trojanowski JQ. Duda JE, et al. Among authors: gollomp sm. J Neuropathol Exp Neurol. 2000 Sep;59(9):830-41. doi: 10.1093/jnen/59.9.830. J Neuropathol Exp Neurol. 2000. PMID: 11005264

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters